Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma

Anti-Cancer Drugs

Volumn 22, Issue 8, 2011, Pages 817-821

  Vaz, Maria Angeles ^a   Pachón, Vanessa ^a   Grande, Enrique ^a   Ferreiro, Reyes ^a   Carrato, Alfredo ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

complete response; renal cell carcinoma; sunitinib; tyrosine kinase inhibitors

Indexed keywords

SUNITINIB;

AGED; ARTICLE; ASPIRATION BIOPSY; CANCER INFILTRATION; CANCER RELAPSE; CANCER SIZE; CASE REPORT; CLEAR CELL CARCINOMA; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCREAS RESECTION; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROPERITONEAL CANCER; SKIN TOXICITY; SPLENECTOMY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRROLES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 80051543746     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283437ff9     Document Type: Article

References (27)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124. (Pubitemid 46089672)
2. Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosin kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008; 78:864-868.
3. Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008; 102:692-696.
4. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008; 180:94-98.
5. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530-2540. (Pubitemid 29368255)
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96. (Pubitemid 351521864)
7. Yagoda A, Bander NH. Failure to cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 1989; 44:338-345. (Pubitemid 20008357)
8. Horoszewick JS, Murphy GP. An assessment of the current use of human interferons in therapy of urological cancers. J Urol 1989; 142:1173-1180. (Pubitemid 19277937)
9. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228:307-319. (Pubitemid 30191694)
10. Kondo K, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001; 264:117-125. (Pubitemid 32989086)
11. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquinination of hypoxia-inducible factor requires direct binding to the betadomain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2:423-427.
12. Atkins MB. Managenent of advanced renal cancer. Kidney Int 2005; 67:2069-2082.
13. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337. (Pubitemid 36109749)
14. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-3590.
15. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al. Renal cell carcinoma guideline. Eur Urol 2007; 51:1502-1510. (Pubitemid 46634775)
16. Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther 2010; 10:305-317.
17. Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I. Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 2006; 5:232-234. (Pubitemid 46190386)
18. Neill MG, Wei AC, Jewett MAS. Consolidative renal cell carcinoma metastasectomy for partial response after multitargeted tyrosin Kinase inhibitor therapy. Urology 2007; 70:178,e9-178,e11.
19. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. Lancet 2007; 370:2103-2111. (Pubitemid 350296300)
20. Locatelli MC, Miedico A, D'Antona A, Longo G, Maggioni M, Maggioni A, et al. Prolonged response to cytoreductive surgery and sunitinib in an elderly patient with synchronous multiple metastases from renal cell carcinoma. Tumori 2010; 96:478-482.
21. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134. (Pubitemid 46089673)
22. Heng DY, Rini BI, Garcia J, Wood L, Bukowski RM. Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma. Clin Genitourin Cancer 2007; 5:446-451. (Pubitemid 351219698)
23. Robert G, Gabbay G, Bram R,Wallerand H, Deminiè re C, Cornelis F, et al. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 2009; 55:1477-1480.
24. Rathmell KA, Amin C,Wallen E, Pruthi R. Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC). In: 2008 ASCO genitourinary cancers symposium [Abstract 370].
25. Zhu X, Stergiopoulus K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009; 48:9-17.
26. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99:81-83.
27. Johannsen M, Flö rcken A, Bex A, Roigas J, Cosentino M, Ficarra V, et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol 2009; 55:1430-1438.